secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001641172-25-025530
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.03, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Biosciences amends merger agreement with Aditxt, exchanges $1.573M notes for Series G-1 Preferred Stock
--------------------------------------------------------------------------------

- Sixth Amendment to A&R Merger Agreement updated definitions to include Series G-1 Preferred, set dissenting share cap at 5,932,818 common shares and 202 preferred shares.
- Exchanged $1.573M aggregate principal of senior secured convertible notes for 1,573 Series G-1 Preferred shares (stated value $1,000/share, conversion price $0.0154).
- Series G-1 Preferred carries voting rights (as-converted), monthly dividends in stock or PIK, and trigger-event conversion at alternative prices with 25% premium.
- Amendment requires waivers from all Series E-1 Preferred holders on price adjustment and other provisions, and updated exchange agreement for convertible noteholders.
- Merger with Aditxt remains pending; proxy statement to be filed for shareholder vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225025530/0001641172-25-025530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225025530/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-025530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer